Bio Path Holdings Stock Performance
BPTH Stock | USD 4.12 0.08 1.98% |
The firm shows a Beta (market volatility) of 0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bio Path's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio Path is expected to be smaller as well. Bio Path Holdings has an expected return of -1.09%. Please make sure to confirm Bio Path Holdings information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Bio Path Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Low | High |
Very Weak
Over the last 90 days Bio Path Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return 0.5 | Five Day Return (11.21) | Year To Date Return (58.98) | Ten Year Return (99.96) | All Time Return (99.84) |
Last Split Factor 1:20 | Dividend Date 2019-01-18 | Last Split Date 2024-02-23 |
1 | symbol Stock Quote Price and Forecast CNN - CNN.com | 01/31/2024 |
2 | Bio-Path Receives New Coverage from Analysts at StockNews.com | 02/08/2024 |
3 | Bio-Path Holdings announces 1-for-20 reverse stock split | 02/21/2024 |
4 | Bio-Path reports FY results | 03/08/2024 |
5 | StockNews.com Begins Coverage on Bio-Path - Defense World | 03/15/2024 |
6 | Acquisition by Michael Garrison of 600 shares of Bio Path at 1.08 subject to Rule 16b-3 | 03/25/2024 |
7 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. Q4 23 | 03/27/2024 |
Begin Period Cash Flow | 10.4 M |
Bio |
Bio Path Relative Risk vs. Return Landscape
If you would invest 926.00 in Bio Path Holdings on December 29, 2023 and sell it today you would lose (514.00) from holding Bio Path Holdings or give up 55.51% of portfolio value over 90 days. Bio Path Holdings is currently does not generate positive expected returns and assumes 6.4252% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Bio Path Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Path's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Path Holdings, and traders can use it to determine the average amount a Bio Path's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1693
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | BPTH |
Estimated Market Risk
6.43 actual daily | 56 56% of assets are less volatile |
Expected Return
-1.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bio Path is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Path by adding Bio Path to a well-diversified portfolio.
Bio Path Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Path, and Bio Path fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
Return On Equity | -2.2 | ||||
Return On Asset | -1.03 | ||||
Current Valuation | 1.79 M | ||||
Shares Outstanding | 678.79 K | ||||
Price To Earning | (6.21) X | ||||
Price To Book | 6.19 X | ||||
EBITDA | (15.66 M) | ||||
Net Income | (16.08 M) | ||||
Cash Per Share | 2.38 X | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 15.57 X | ||||
Cash Flow From Operations | (11.54 M) | ||||
Earnings Per Share | (33.63) X | ||||
Total Asset | 3.22 M | ||||
Retained Earnings | (107.61 M) | ||||
Current Asset | 9.59 M | ||||
About Bio Path Performance
To evaluate Bio Path Holdings Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bio Path generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bio Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bio Path Holdings market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Bio's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | (12.06) | (11.45) | |
Return On Assets | (4.99) | (4.74) | |
Return On Equity | (36.46) | (34.64) |
Things to note about Bio Path Holdings performance evaluation
Checking the ongoing alerts about Bio Path for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Path Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Bio Path Holdings generated a negative expected return over the last 90 days | |
Bio Path Holdings has high historical volatility and very poor performance | |
Bio Path Holdings has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
Latest headline from finance.yahoo.com: Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. Q4 23 |
- Analyzing Bio Path's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Path's stock is overvalued or undervalued compared to its peers.
- Examining Bio Path's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Path's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Path's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Path's stock. These opinions can provide insight into Bio Path's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.